Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, has announced it will release its first quarter 2025 financial results and corporate highlights on Monday, May 5, 2025. The announcement will be made after U.S. financial markets close.
The company, based in Cambridge, Massachusetts, specializes in transforming drug discovery through a combination of:
- Leading-edge computational technologies
- Experimental technologies
This upcoming financial disclosure represents a standard quarterly reporting event for the precision medicine developer, providing stakeholders with insights into the company's financial performance and operational progress for Q1 2025.
Relay Therapeutics (Nasdaq: RLAY), un'azienda in fase clinica specializzata in medicina di precisione, ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 e gli aggiornamenti aziendali il lunedì 5 maggio 2025. L'annuncio avverrà dopo la chiusura dei mercati finanziari statunitensi.
L'azienda, con sede a Cambridge, Massachusetts, si dedica a rivoluzionare la scoperta di farmaci attraverso una combinazione di:
- Tecnologie computazionali all'avanguardia
- Tecnologie sperimentali
Questa prossima comunicazione finanziaria rappresenta un evento standard di rendicontazione trimestrale per lo sviluppatore di medicina di precisione, offrendo agli stakeholder una visione sulle performance finanziarie e i progressi operativi dell'azienda per il primo trimestre 2025.
Relay Therapeutics (Nasdaq: RLAY), una empresa en etapa clínica especializada en medicina de precisión, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 y aspectos corporativos el lunes 5 de mayo de 2025. El anuncio se realizará después del cierre de los mercados financieros de EE. UU.
La compañía, con sede en Cambridge, Massachusetts, se especializa en transformar el descubrimiento de fármacos mediante una combinación de:
- Tecnologías computacionales de vanguardia
- Tecnologías experimentales
Esta próxima divulgación financiera representa un evento estándar de reporte trimestral para el desarrollador de medicina de precisión, brindando a los interesados información sobre el desempeño financiero y los avances operativos de la empresa en el primer trimestre de 2025.
Relay Therapeutics (나스닥: RLAY)은 임상 단계의 정밀 의학 회사로서 2025년 1분기 재무 결과와 기업 주요 사항을 2025년 5월 5일 월요일에 발표할 예정이라고 밝혔습니다. 발표는 미국 금융 시장 마감 후에 이루어집니다.
매사추세츠주 케임브리지에 본사를 둔 이 회사는 다음의 결합을 통해 신약 개발을 혁신하는 데 주력하고 있습니다:
- 최첨단 컴퓨터 기술
- 실험 기술
이번 재무 공개는 정밀 의학 개발사로서의 표준 분기 보고 행사로, 2025년 1분기 동안 회사의 재무 성과와 운영 진행 상황에 대한 통찰을 이해관계자들에게 제공합니다.
Relay Therapeutics (Nasdaq : RLAY), une entreprise en phase clinique spécialisée dans la médecine de précision, a annoncé qu'elle publierait ses résultats financiers du premier trimestre 2025 et ses faits marquants d'entreprise le lundi 5 mai 2025. L'annonce sera faite après la fermeture des marchés financiers américains.
Basée à Cambridge, Massachusetts, la société se spécialise dans la transformation de la découverte de médicaments grâce à une combinaison de :
- Technologies informatiques de pointe
- Technologies expérimentales
Cette prochaine communication financière constitue un événement standard de reporting trimestriel pour ce développeur en médecine de précision, offrant aux parties prenantes un aperçu des performances financières et des progrès opérationnels de l'entreprise pour le premier trimestre 2025.
Relay Therapeutics (Nasdaq: RLAY), ein klinisch fortgeschrittenes Präzisionsmedizin-Unternehmen, hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 und Unternehmens-Highlights am Montag, den 5. Mai 2025 zu veröffentlichen. Die Bekanntgabe erfolgt nach Börsenschluss in den USA.
Das in Cambridge, Massachusetts ansässige Unternehmen spezialisiert sich darauf, die Wirkstoffentdeckung durch eine Kombination aus:
- Modernsten computergestützten Technologien
- Experimentellen Technologien
Diese bevorstehende Finanzmitteilung stellt ein reguläres Quartalsberichtsereignis für den Entwickler von Präzisionsmedizin dar und bietet den Interessengruppen Einblicke in die finanzielle Leistung und den operativen Fortschritt des Unternehmens für das erste Quartal 2025.
- Company maintains status as a clinical-stage precision medicine company
- Demonstrates continued operation of their unique drug discovery platform combining computational and experimental technologies
- None.
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics (RLAY) release Q1 2025 earnings?
What will Relay Therapeutics Q1 2025 earnings report include?
Where is Relay Therapeutics (RLAY) headquartered?
What type of company is Relay Therapeutics (RLAY)?
Which stock exchange is Relay Therapeutics listed on?
